Literature DB >> 25107591

Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.

Bronwyn Kivell1, Zeljko Uzelac2, Santhanalakshmi Sundaramurthy3, Jeyaganesh Rajamanickam3, Amy Ewald4, Vladimir Chefer5, Vanaja Jaligam5, Elizabeth Bolan5, Bridget Simonson4, Balasubramaniam Annamalai6, Padmanabhan Mannangatti3, Thomas E Prisinzano7, Ivone Gomes8, Lakshmi A Devi8, Lankupalle D Jayanthi3, Harald H Sitte2, Sammanda Ramamoorthy9, Toni S Shippenberg5.   

Abstract

Salvinorin A (SalA), a selective κ-opioid receptor (KOR) agonist, produces dysphoria and pro-depressant like effects. These actions have been attributed to inhibition of striatal dopamine release. The dopamine transporter (DAT) regulates dopamine transmission via uptake of released neurotransmitter. KORs are apposed to DAT in dopamine nerve terminals suggesting an additional target by which SalA modulates dopamine transmission. SalA produced a concentration-dependent, nor-binaltorphimine (BNI)- and pertussis toxin-sensitive increase of ASP(+) accumulation in EM4 cells coexpressing myc-KOR and YFP-DAT, using live cell imaging and the fluorescent monoamine transporter substrate, trans 4-(4-(dimethylamino)-styryl)-N-methylpyridinium) (ASP(+)). Other KOR agonists also increased DAT activity that was abolished by BNI pretreatment. While SalA increased DAT activity, SalA treatment decreased serotonin transporter (SERT) activity and had no effect on norepinephrine transporter (NET) activity. In striatum, SalA increased the Vmax for DAT mediated DA transport and DAT surface expression. SalA up-regulation of DAT function is mediated by KOR activation and the KOR-linked extracellular signal regulated kinase-½ (ERK1/2) pathway. Co-immunoprecipitation and BRET studies revealed that DAT and KOR exist in a complex. In live cells, DAT and KOR exhibited robust FRET signals under basal conditions. SalA exposure caused a rapid and significant increase of the FRET signal. This suggests that the formation of KOR and DAT complexes is promoted in response to KOR activation. Together, these data suggest that enhanced DA transport and decreased DA release resulting in decreased dopamine signalling may contribute to the dysphoric and pro-depressant like effects of SalA and other KOR agonists.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Dopamine transporter; Dysphoric; Kappa opioid receptor; Pro-depressant; Salvinorin A; Serotonin transporter; Trafficking

Mesh:

Substances:

Year:  2014        PMID: 25107591      PMCID: PMC4188751          DOI: 10.1016/j.neuropharm.2014.07.016

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  81 in total

1.  A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer.

Authors:  John R James; Marta I Oliveira; Alexandre M Carmo; Andrea Iaboni; Simon J Davis
Journal:  Nat Methods       Date:  2006-11-05       Impact factor: 28.547

2.  Regulation of dopamine transporter function and cell surface expression by D3 dopamine receptors.

Authors:  Agustin Zapata; Bronwyn Kivell; Yang Han; Jonathan A Javitch; Elizabeth A Bolan; David Kuraguntla; Vanaja Jaligam; Murat Oz; Lankupalle D Jayanthi; Devadoss J Samuvel; Sammanda Ramamoorthy; Toni S Shippenberg
Journal:  J Biol Chem       Date:  2007-10-08       Impact factor: 5.157

3.  Effects of salvinorin A, a kappa-opioid hallucinogen, on a neuroendocrine biomarker assay in nonhuman primates with high kappa-receptor homology to humans.

Authors:  Eduardo R Butelman; Marek Mandau; Kevin Tidgewell; Thomas E Prisinzano; Vadim Yuferov; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2006-10-23       Impact factor: 4.030

4.  Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.

Authors:  Romina Mizrahi; Pablo Rusjan; Ofer Agid; Ariel Graff; David C Mamo; Robert B Zipursky; Shitij Kapur
Journal:  Am J Psychiatry       Date:  2007-04       Impact factor: 18.112

Review 5.  Salvinorin A: from natural product to human therapeutics.

Authors:  Timothy A Vortherms; Bryan L Roth
Journal:  Mol Interv       Date:  2006-10

6.  Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor.

Authors:  Frank J S Lee; Lin Pei; Anna Moszczynska; Brian Vukusic; Paul J Fletcher; Fang Liu
Journal:  EMBO J       Date:  2007-03-22       Impact factor: 11.598

7.  Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport.

Authors:  Jacob U Fog; Habibeh Khoshbouei; Marion Holy; William A Owens; Christian Bjerggaard Vaegter; Namita Sen; Yelyzaveta Nikandrova; Erica Bowton; Douglas G McMahon; Roger J Colbran; Lynette C Daws; Harald H Sitte; Jonathan A Javitch; Aurelio Galli; Ulrik Gether
Journal:  Neuron       Date:  2006-08-17       Impact factor: 17.173

8.  D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism.

Authors:  Elizabeth A Bolan; Bronwyn Kivell; Vanaja Jaligam; Murat Oz; Lankupalle D Jayanthi; Yang Han; Namita Sen; Eneki Urizar; Ivone Gomes; Lakshmi A Devi; Sammanda Ramamoorthy; Jonathan A Javitch; Agustin Zapata; Toni S Shippenberg
Journal:  Mol Pharmacol       Date:  2007-01-31       Impact factor: 4.436

9.  Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching.

Authors:  Erika M Adkins; Devadoss J Samuvel; Jacob U Fog; Jacob Eriksen; Lankupalle D Jayanthi; Christian Bjerggaard Vaegter; Sammanda Ramamoorthy; Ulrik Gether
Journal:  Biochemistry       Date:  2007-08-22       Impact factor: 3.162

Review 10.  Dynorphin and the pathophysiology of drug addiction.

Authors:  T S Shippenberg; A Zapata; V I Chefer
Journal:  Pharmacol Ther       Date:  2007-07-24       Impact factor: 12.310

View more
  42 in total

1.  A Role for p38 Mitogen-activated Protein Kinase-mediated Threonine 30-dependent Norepinephrine Transporter Regulation in Cocaine Sensitization and Conditioned Place Preference.

Authors:  Padmanabhan Mannangatti; Kamalakkannan NarasimhaNaidu; Mohamad Imad Damaj; Sammanda Ramamoorthy; Lankupalle Damodara Jayanthi
Journal:  J Biol Chem       Date:  2015-02-27       Impact factor: 5.157

2.  Voluntary ethanol intake predicts κ-opioid receptor supersensitivity and regionally distinct dopaminergic adaptations in macaques.

Authors:  Cody A Siciliano; Erin S Calipari; Verginia C Cuzon Carlson; Christa M Helms; David M Lovinger; Kathleen A Grant; Sara R Jones
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

3.  Long-term plasticity of corticostriatal synapses is modulated by pathway-specific co-release of opioids through κ-opioid receptors.

Authors:  Sarah L Hawes; Armando G Salinas; David M Lovinger; Kim T Blackwell
Journal:  J Physiol       Date:  2017-05-26       Impact factor: 5.182

4.  A Mutation in Hnrnph1 That Decreases Methamphetamine-Induced Reinforcement, Reward, and Dopamine Release and Increases Synaptosomal hnRNP H and Mitochondrial Proteins.

Authors:  Qiu T Ruan; Neema Yazdani; Benjamin C Blum; Jacob A Beierle; Weiwei Lin; Michal A Coelho; Elissa K Fultz; Aidan F Healy; John R Shahin; Amarpreet K Kandola; Kimberly P Luttik; Karen Zheng; Nathaniel J Smith; Justin Cheung; Farzad Mortazavi; Daniel J Apicco; Durairaj Ragu Varman; Sammanda Ramamoorthy; Peter E A Ash; Douglas L Rosene; Andrew Emili; Benjamin Wolozin; Karen K Szumlinski; Camron D Bryant
Journal:  J Neurosci       Date:  2019-11-08       Impact factor: 6.167

5.  MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.

Authors:  Diana V Atigari; Rajendra Uprety; Gavril W Pasternak; Susruta Majumdar; Bronwyn M Kivell
Journal:  Neuropharmacology       Date:  2019-02-13       Impact factor: 5.250

6.  Enhanced Dopamine Release by Dopamine Transport Inhibitors Described by a Restricted Diffusion Model and Fast-Scan Cyclic Voltammetry.

Authors:  Alexander F Hoffman; Charles E Spivak; Carl R Lupica
Journal:  ACS Chem Neurosci       Date:  2016-03-28       Impact factor: 4.418

7.  The Atypical MAP Kinase SWIP-13/ERK8 Regulates Dopamine Transporters through a Rho-Dependent Mechanism.

Authors:  Daniel P Bermingham; J Andrew Hardaway; Osama Refai; Christian R Marks; Sam L Snider; Sarah M Sturgeon; William C Spencer; Roger J Colbran; David M Miller; Randy D Blakely
Journal:  J Neurosci       Date:  2017-08-21       Impact factor: 6.167

8.  Modulation of serotonin transporter function by kappa-opioid receptor ligands.

Authors:  Santhanalakshmi Sundaramurthy; Balasubramaniam Annamalai; Devadoss J Samuvel; Toni S Shippenberg; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  Neuropharmacology       Date:  2016-10-12       Impact factor: 5.250

9.  Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome.

Authors:  Shangru Lyu; Mark P DeAndrade; Stefan Mueller; Alexander Oksche; Arthur S Walters; Yuqing Li
Journal:  Behav Brain Res       Date:  2019-07-31       Impact factor: 3.332

Review 10.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.